CJC-1295

What is CJC-1295?

CJC-1295 is a lab-made peptide that copies a natural signal called growth-hormone-releasing hormone (GHRH), the brain’s message telling the pituitary to put out growth hormone. Its trick is staying around far longer than the natural version. One form, sometimes labeled “with DAC,” is engineered to bind to a blood protein so it lingers for days instead of minutes. People often pair it with ipamorelin so one drug tells the pituitary “release” while the other amplifies the pulse. Like the others here, CJC-1295 is not FDA-approved and is sold only as a research chemical.

What does CJC-1295 claim to do?

The pitch is sustained, elevated growth hormone and IGF-1 from infrequent dosing. Claimed payoffs: more muscle, less fat, better recovery and sleep, healthier skin, and a general anti-aging glow. The “DAC” long-acting version is marketed as convenient because it’s said to keep hormone levels raised continuously rather than in brief spikes.

Why do people use CJC-1295?

Convenience and synergy drive its popularity. The idea of a once-or-twice-weekly injection that keeps growth hormone elevated appeals to people who don’t want daily shots. In peptide circles, the “CJC-1295 plus ipamorelin” stack is almost a default recommendation, passed around as a recovery and body-composition tool.

What does the science actually say about CJC-1295?

The honest picture: CJC-1295 does raise growth hormone and IGF-1 in humans. That was shown in small early-phase studies, and the long-acting version produced sustained increases over days. So the pharmacology is real and somewhat better documented than for ipamorelin. But the studies were small, short, and focused on whether hormone levels moved, not on whether people got healthier, fitter, or aged more slowly. There is no body of trials showing meaningful real-world benefit, and certainly none showing long-term safety.

There’s also a conceptual wrinkle. The body normally releases growth hormone in pulses, and that pulsing pattern seems to matter biologically. The long-acting form deliberately flattens those pulses into a continuous elevation, which is exactly the unnatural pattern that injected synthetic growth hormone creates, the kind associated with side effects. Pushing IGF-1 up continuously is also the signaling direction that some aging research links to faster aging and higher cancer risk, not slower. None of this has been measured properly for CJC-1295.

How do people use CJC-1295?

For information only: CJC-1295 is described in the literature as an injected peptide, dosed in microgram amounts, with the no-DAC version taken more frequently and the DAC version less often because it lasts longer. It is commonly combined with a GHRP. This book provides no sourcing, mixing, or injection guidance, and there is no established safe human dose because it is not an approved drug. Bloodwork and medical supervision are essential for anyone exploring it.

Is CJC-1295 safe? Risks and who should skip it

Expected risks track with raising growth hormone: water retention, joint and muscle aching, carpal-tunnel-like tingling, and shifts in blood sugar. Continuous elevation may carry more risk than natural pulses. The cell-growth concern means anyone with a cancer history should avoid it. Do not use if pregnant, breastfeeding, diabetic, hormone-sensitive, under 25, or on other medications without oversight. Research-chemical purity is unverified and a real safety issue.

The bottom line on CJC-1295

CJC-1295 is a credible growth-hormone-raising peptide with thin human-benefit evidence and no long-term safety data, and it is not FDA-approved. The long-acting “always on” version may trade away the natural pulsing the body seems to prefer. Worth understanding; only ever a supervised, eyes-open experiment.